

# Takuji Okusaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8008999/publications.pdf>

Version: 2024-02-01

123  
papers

13,028  
citations

53660

45  
h-index

24179

110  
g-index

124  
all docs

124  
docs citations

124  
times ranked

13592  
citing authors

#	ARTICLE	IF	CITATIONS
1	One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry. <i>Thrombosis Research</i> , 2022, 213, 203-213.	0.8	12
2	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 354-367.	4.2	44
3	Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. <i>Liver Cancer</i> , 2022, 11, 290-314.	4.2	30
4	Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 383-400.	1.1	20
5	Safety, tolerability, and anti-fibrotic efficacy of the CBP/ $\beta$ -catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. <i>EBioMedicine</i> , 2022, 80, 104069.	2.7	16
6	Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. <i>JCO Oncology Practice</i> , 2021, 17, e416-e425.	1.4	12
7	Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population. <i>Journal of Human Genetics</i> , 2021, 66, 139-149.	1.1	17
8	Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity. <i>Frontiers in Genetics</i> , 2021, 12, 652704.	1.1	9
9	Cholangiocarcinoma: is it time for a revolution?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 467-470.	1.4	1
10	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. <i>Journal of Gastroenterology</i> , 2021, 56, 570-580.	2.3	6
11	A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2065-2072.	1.0	5
12	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	0.8	257
13	Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 965-971.	0.5	1
14	A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 3759-3769.	1.7	29
15	Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1246-1253.	0.6	43
16	Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). <i>International Journal of Clinical Oncology</i> , 2020, 25, 1835-1843.	1.0	6
17	Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society. <i>Pancreas</i> , 2020, 49, 326-335.	0.5	125
18	Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. <i>Nature Communications</i> , 2020, 11, 3175.	5.8	34

#	ARTICLE	IF	CITATIONS
19	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	1.9	26
20	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. <i>Journal of Gastroenterology</i> , 2020, 55, 369-382.	2.3	48
21	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25
22	Chemotherapy for patients with unresectable pancreatic cancer is recommended in the Clinical Practice Guidelines for Pancreatic Cancer 2019. <i>Suizo</i> , 2020, 35, 69-74.	0.1	0
23	What determines the timing of discussions on forgoing anticancer treatment? A national survey of medical oncologists. <i>Supportive Care in Cancer</i> , 2019, 27, 1375-1382.	1.0	10
24	Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines. <i>Cells</i> , 2019, 8, 1026.	1.8	2
25	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased $\alpha$ -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296.	5.1	1,202
26	A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) $\pm$ chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS465-TPS465.	0.8	36
27	A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 1017-1023.	1.1	103
28	Chemotherapy for hepatocellular carcinoma: current status and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 103-114.	0.6	192
29	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. <i>Journal of Gastroenterology</i> , 2018, 53, 281-290.	2.3	42
30	Immunotherapy for hepatocellular carcinoma: current status and future perspectives. <i>ESMO Open</i> , 2018, 3, e000455.	2.0	76
31	Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). <i>Pancreatology</i> , 2018, 18, 841-845.	0.5	23
32	A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4076-4076.	0.8	101
33	Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1053-1059.	1.2	24
34	Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society. <i>Pancreas</i> , 2017, 46, 595-604.	0.5	116
35	Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1138-1147.	1.0	81
36	Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 832-839.	0.6	9

#	ARTICLE	IF	CITATIONS
37	A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 512-519.	0.6	14
38	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	1.1	16
39	Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2017, 52, 512-519.	2.3	275
40	Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. <i>Cancer Science</i> , 2016, 107, 1791-1799.	1.7	6
41	Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 1385-1394.	3.2	150
42	Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 628-633.	1.4	20
43	Phase I study of tivatinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. <i>Cancer Science</i> , 2015, 106, 611-617.	1.7	21
44	Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. <i>Cancer Science</i> , 2015, 106, 883-890.	1.7	78
45	Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?. <i>Cancer Science</i> , 2015, 106, 1101-1102.	1.7	3
46	Phase 1 and pharmacological trial of OPB1121, a signal transducer and activator of transcription inhibitor, in patients with advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 1283-1291.	1.8	61
47	Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 360-381.	1.0	41
48	Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. <i>Journal of Gastroenterology</i> , 2015, 50, 667-674.	2.3	36
49	Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 221-229.	3.3	12
50	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 859-870.	5.1	699
51	Clinical practice guidelines for the management of biliary tract cancers 2015: the 2 <sup>nd</sup> English edition. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 249-273.	1.4	205
52	A National Survey to Systematically Identify Factors Associated With Oncologists' Attitudes Toward End-of-Life Discussions: What Determines Timing of End-of-Life Discussions?. <i>Oncologist</i> , 2015, 20, 1304-1311.	1.9	56
53	Genomic spectra of biliary tract cancer. <i>Nature Genetics</i> , 2015, 47, 1003-1010.	9.4	907
54	Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. <i>Journal of Gastroenterology</i> , 2015, 50, 191-202.	2.3	76

#	ARTICLE	IF	CITATIONS
55	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
56	Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. <i>Cancer Science</i> , 2014, 105, 1321-1326.	1.7	156
57	Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2014, 21, 761-766.	1.4	25
58	Emerging drugs for biliary cancer. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 11-24.	1.0	6
59	Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. <i>Hepatology Research</i> , 2014, 44, 1268-1276.	1.8	24
60	Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. <i>Hepatology</i> , 2014, 59, 1427-1434.	3.6	420
61	Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 442-447.	0.6	13
62	EBM-based Clinical Guidelines for Pancreatic Cancer (2013) Issued by the Japan Pancreas Society: A Synopsis. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 883-888.	0.6	41
63	A Multicenter Phase II Trial of S-1 With Concurrent Radiation Therapy for Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 163-169.	0.4	54
64	Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 207-213.	1.0	75
65	The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): History and Future Direction. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 2-7.	0.6	4
66	Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japanese Clinical Oncology Group trial (JCOG 0805). <i>Cancer Science</i> , 2013, 104, 1211-1216.	1.7	99
67	Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1640-1648.	0.8	548
68	Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment. <i>Case Reports in Oncology</i> , 2013, 6, 531-537.	0.3	2
69	Current status of hepatocellular carcinoma in Japan. <i>Chinese Clinical Oncology</i> , 2013, 2, 40.	0.4	20
70	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 2015-2025.	1.2	31
71	Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. <i>BMC Cancer</i> , 2012, 12, 609.	1.1	11
72	Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FCS) in gemcitabine-refractory pancreatic cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 957-964.	1.1	8

#	ARTICLE	IF	CITATIONS
73	Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-1 trial). <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 314-318.	1.4	12
74	Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma. <i>Cancer Science</i> , 2012, 103, 1524-1530.	1.7	7
75	Everolimus for Advanced Pancreatic Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2011, 364, 514-523.	13.9	2,547
76	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 256-262.	5.1	356
77	Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. <i>Hepatology Research</i> , 2011, 41, 542-552.	1.8	23
78	Phase I Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer. <i>Journal of Immunotherapy</i> , 2011, 34, 92-99.	1.2	91
79	Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2011, 40, 415-421.	0.5	35
80	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. <i>Cancer Science</i> , 2011, 102, 425-431.	1.7	51
81	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 31-39.	2.0	33
82	Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 953-958.	0.6	44
83	Targeted Therapy for Biliary Tract Cancer. <i>Cancers</i> , 2011, 3, 2243-2254.	1.7	14
84	Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. <i>Cancer Science</i> , 2010, 101, 882-888.	1.7	23
85	Randomized Phase II Study of Gemcitabine plus S-1 Combination Therapy vs. S-1 in Advanced Biliary Tract Cancer: Japan Clinical Oncology Group Study (JCOG0805). <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 1189-1191.	0.6	13
86	Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases. <i>Oncology</i> , 2010, 79, 39-45.	0.9	23
87	Genome-Wide Association Study of Pancreatic Cancer in Japanese Population. <i>PLoS ONE</i> , 2010, 5, e11824.	1.1	126
88	Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 797-806.	0.6	55
89	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 313-319.	1.1	89
90	A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 113-120.	1.1	21

#	ARTICLE	IF	CITATIONS
91	Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial. <i>Journal of Hepatology</i> , 2009, 51, 1030-1036.	1.8	90
92	A late phase II study of S-1 for metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 615-621.	1.1	156
93	S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 849-855.	1.1	132
94	Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan. <i>International Journal of Clinical Oncology</i> , 2008, 13, 127-131.	1.0	6
95	Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 755-761.	0.6	46
96	A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 447-454.	1.1	47
97	Spontaneous regression of hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2006, 11, 407-411.	1.0	42
98	Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 647-653.	1.1	138
99	A Phase I/II Study of Combination Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 557-563.	0.6	14
100	Early Phase II Study of Uracilâ€“Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 552-556.	0.6	27
101	Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer. <i>Anticancer Research</i> , 2006, 26, 3755-9.	0.5	15
102	A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 756-762.	2.0	71
103	An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer. <i>Oncology</i> , 2005, 68, 171-178.	0.9	110
104	Chemoradiotherapy for Locally Advanced Pancreatic Carcinoma in Elderly Patients. <i>Oncology</i> , 2005, 68, 432-437.	0.9	18
105	A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer. <i>Oncology</i> , 2005, 69, 421-427.	0.9	49
106	Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma. <i>Investigational New Drugs</i> , 2004, 22, 169-176.	1.2	67
107	New approaches for pancreatic cancer in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54 Suppl 1, S78-82.	1.1	3
108	Systemic Chemotherapy for Pancreatic Cancer. <i>Pancreas</i> , 2004, 28, 301-304.	0.5	19

#	ARTICLE	IF	CITATIONS
109	Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. <i>Radiotherapy and Oncology</i> , 2003, 67, 327-330.	0.3	8
110	Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer. <i>Oncology</i> , 2003, 64, 475-476.	0.9	22
111	Transcatheter Arterial Embolization with Zinostatin Stimalamer for Hepatocellular Carcinoma. <i>Oncology</i> , 2002, 62, 228-233.	0.9	24
112	Phase II Study of Uracil-Tegafur in Patients with Metastatic Pancreatic Cancer. <i>Oncology</i> , 2002, 62, 223-227.	0.9	22
113	Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. <i>Cancer</i> , 2002, 95, 1931-1937.	2.0	205
114	Chemotherapy for biliary tract cancer in Japan. <i>Seminars in Oncology</i> , 2002, 29, 51-53.	0.8	159
115	Abdominal Pain in Patients with Resectable Pancreatic Cancer with Reference to Clinicopathologic Findings. <i>Pancreas</i> , 2001, 22, 279-284.	0.5	31
116	Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. <i>Cancer</i> , 2001, 91, 1384-1389.	2.0	16
117	Evaluation of the Therapeutic Effect of Transcatheter Arterial Embolization for Hepatocellular Carcinoma. <i>Oncology</i> , 2000, 58, 293-299.	0.9	46
118	Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy. <i>Oncology</i> , 2000, 59, 296-301.	0.9	86
119	Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection. , 1998, 82, 1638-1642.		105
120	Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma. <i>Oncology</i> , 1998, 55, 276-283.	0.9	27
121	Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. , 1997, 79, 1516-1520.		102
122	A Phase II Study of Cisplatin in Patients with Biliary Tract Carcinoma. <i>Oncology</i> , 1994, 51, 515-517.	0.9	53
123	The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	1